IVDR Fees and Cost Structure: Four Budget Lines You Must Separate
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The IVDR does not have a single application fee payable at EU level. Spending is distributed across four categories: conformity assessment fees charged by notified bodies (Article 46 requires the Commission to publish standard fee schedules); fees charged by EU reference laboratories under Article 100(7) (detailed in (EU) 2022/945); charges levied by Member States for registration and related activities under Article 104 (which must be transparent and based on cost recovery, with the structure notified to the Commission and other Member States 3 months in advance); and internal compliance build-up costs within the company. No official source publishes concrete amount ranges, and this series does not cite them. The practical takeaway for budget planning is structural, not numerical: each of the four categories follows a different pricing logic, arrives at a different point in the project timeline, and requires its own legal source to be cited in the budget line, so a single blended figure of what an IVDR certification costs is inherently unreliable.
2. Legal basis
| Regulation / document | Provision | Date | Source |
|---|---|---|---|
| Regulation (EU) 2017/746 (IVDR) | Article 46 (standard fee schedules); Articles 104(1)(2) (Member State fees: transparency plus cost recovery; notification 3 months in advance) | Adopted 2017-04-05; Chapter covering Articles 31–46, including Article 46, applies from 2017-11-26 | EUR-Lex |
| Same document | Article 100(7)(8) (EURLs may charge notified bodies and Member States; the Commission sets the structure and level by implementing regulation) | 2017-04-05 | EUR-Lex |
| Implementing Regulation (EU) 2022/945 | Fees that EURLs may charge notified bodies and Member States | 2022 | EUR-Lex |
| Implementing Regulation (EU) 2026/977 | Lowest-quotation content; prior written justification for fee increases above 10%; annual median fee and on-time completion reporting (Article 4(4) from 2028-01-01) | Applicable from 2027-02-25 | EUR-Lex |
3. Expert insights
Insight 1: The four categories of spending follow completely different pricing logics.
Notified bodies operate on market pricing (Article 46 only requires the publication of standard fee schedules); EURLs apply cost-covering pricing with conditions determined in advance and made transparent (Article 100(7)); Member States apply cost-recovery pricing (Article 104(1)); and internal costs follow project pricing. Mixing the four into a single figure for what an IVDR certification costs is necessarily distorted: the notified body quote responds to scope and class, the EURL fees respond to the batch verification and performance verification workload, the Member State charges respond to national fee ordinances, and internal costs respond to the maturity of the existing quality system. Budget documents should keep the four lines separate with their legal sources attached.
Insight 2: The fee structure of Class D differs from Classes B and C by an order of magnitude.
Class D devices add EURL performance verification and batch verification (Article 48(5), Annex IX Section 4.12, Annex XI Section 5.1), expert opinion where applicable (Article 48(6)), and the review mechanism of Article 50. None of these elements exists in Class B and C projects, so fee experience from Class B cannot be extrapolated to Class D. When planning a Class D submission, budget owners should also expect longer timelines driven by the EURL and the expert panel, which translates into more surveillance and unannounced audits within the notified body quote and higher internal effort over the same calendar period.
Insight 3: (EU) 2026/977 significantly changes fee predictability.
This implementing regulation applies from 2027-02-25: quotations must include at least (1) the overall estimated fee, broken down by quality management system audit and technical documentation assessment where applicable, including routine surveillance and unannounced audit fees; (2) an estimate of potential additional spending calculated on an hourly rate basis (only where the duration cannot be determined in advance); and (3) an estimated timeline. Where actual fees exceed the quoted estimate by more than 10%, the notified body must provide a written justification in advance. From 2028 onwards, notified bodies must also publish by 30 April each year the median fees and on-time completion rates of the previous year. Procurement teams can use these publications to benchmark quotes before the underlying data becomes routine.
Insight 4: Internal compliance costs are the most frequently underestimated line.
Technical documentation (Annexes II and III), performance evaluation and the performance evaluation report (Article 56), the quality management system (13 aspects under Article 10(8)), the PRRC (Article 15), UDI and EUDAMED data maintenance (Articles 24–28), and PSURs and vigilance (Articles 81–83) constitute recurring spending whose magnitude often exceeds the one-off certification fee. Companies budgeting only for the notified body quote systematically understate the true cost of IVDR compliance, and the gap usually appears in the second and third year, when updates, audits and data maintenance become due.
4. Practical recommendations
- Prepare the budget in four separate categories: notified body, EURL, Member State charges and internal compliance, each with its legal source stated.
- List EURL fees separately for Class D projects and check them against (EU) 2022/945.
- Frame quotations to the requirements of (EU) 2026/977: itemised quote plus timeline, with prior written notice agreed for increases above 10%.
- Build a three-year rolling budget for recurring internal spending (annual performance evaluation report updates, PSURs, data maintenance).
- Do not cite any amount range without an official source (this series adopts none).
5. Verification checklist
- □ Budget prepared in the four categories: notified body, EURL, Member State and internal
- □ Notified body quotations requested in the itemised form of (EU) 2026/977 (applicable from 2027-02-25)
- □ EURL fees listed separately per (EU) 2022/945
- □ Member State registration charges included in the annual budget per Article 104
- □ Recurring internal compliance spending on a three-year rolling budget
- □ No amount range without an official source adopted
Legal information verified as of 2026-10-29.
GRZAN supports in vitro diagnostic manufacturers entering the EU market under Regulation (EU) 2017/746 as EU Authorised Representative (EC REP) and PRRC provider, including fee budgeting across notified body, EURL and Member State charges, quotation reviews aligned to (EU) 2026/977 and multi-year compliance budget planning. For IVDR fee and budget support, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us